Education
About Us
Working with TipRanks
Follow Us
Bausch Health Companies (TSE:BHC)
TSX:BHC
BHC Stock Chart & Stats
C$8.37
-C$0.04(-0.35%)
At close: 4:00 PM EST
C$8.37
-C$0.04(-0.35%)
Day’s Range― - ―
52-Week RangeC$5.91 - C$11.97
Previous CloseN/A
Volume45.48K
Average Volume (3M)573.78K
Market Cap
C$3.15B
Enterprise ValueC$22.11B
Total Cash (Recent Filing)C$1.32B
Total Debt (Recent Filing)C$21.21B
Price to Earnings (P/E)14.6
Beta1.23
Next Earnings
Apr 30, 2026EPS Estimate
0.97Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.47
Shares Outstanding370,516,940
10 Day Avg. Volume652,949
30 Day Avg. Volume573,784
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)-4.65
Price to Sales (P/S)0.25
P/FCF Ratio2.64
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$10.25Price Target Upside22.44% Upside
Rating ConsensusHold
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Guidance — Upgraded OutlookCompany issued guidance above prior analyst estimates, implying management expects improved top-line growth and offering clearer upside to the sales outlook.
Pipeline — Larsucosterol OpportunityInvestor focus on larsucosterol as a potential first approved treatment for severe alcohol-associated hepatitis could create a meaningful new commercial revenue stream if regulatory approval is achieved.
Revenue — Vision Care SegmentTotal revenue exceeded analysts' estimates due to strong sales in the vision care segment, indicating resilient demand that could support higher future revenue.
Bears Say
Clinical Setback — RED-C Program FailurePhase three RED-C program not meeting its primary endpoint undermines the commercial prospects for the rifaximin SSD asset and increases pressure on future pipeline-driven revenue.
Earnings Quality — Elevated Tax RateEarnings per share missed forecasts because an unexpectedly high effective tax rate reduced reported profitability, weakening near-term earnings visibility.
Loss Of Exclusivity — XifaxanLoss of exclusivity for Xifaxan represents a major overhang on sales, increasing the need to replace revenue as pricing and market share come under pressure.
Bausch Health Companies News
BHC FAQ
What was Bausch Health Companies’s price range in the past 12 months?
Bausch Health Companies lowest stock price was C$5.91 and its highest was C$11.97 in the past 12 months.
What is Bausch Health Companies’s market cap?
Bausch Health Companies’s market cap is C$3.15B.
When is Bausch Health Companies’s upcoming earnings report date?
Bausch Health Companies’s upcoming earnings report date is Apr 30, 2026 which is in 65 days.
How were Bausch Health Companies’s earnings last quarter?
Bausch Health Companies released its earnings results on Feb 18, 2026. The company reported C$1.473 earnings per share for the quarter, missing the consensus estimate of C$1.666 by -C$0.193.
Is Bausch Health Companies overvalued?
According to Wall Street analysts Bausch Health Companies’s price is currently Undervalued.
Does Bausch Health Companies pay dividends?
Bausch Health Companies pays a Quarterly dividend of C$0.097 which represents an annual dividend yield of N/A. See more information on Bausch Health Companies dividends here
What is Bausch Health Companies’s EPS estimate?
Bausch Health Companies’s EPS estimate is 0.97.
How many shares outstanding does Bausch Health Companies have?
Bausch Health Companies has 370,516,940 shares outstanding.
What happened to Bausch Health Companies’s price movement after its last earnings report?
Bausch Health Companies reported an EPS of C$1.473 in its last earnings report, missing expectations of C$1.666. Following the earnings report the stock price went down -4.7%.
Which hedge fund is a major shareholder of Bausch Health Companies?
Currently, no hedge funds are holding shares in TSE:BHC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bausch Health Companies Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
C$10.25 (22.44% Upside)
C$10.25 (22.44% Upside)
Blogger Sentiment
Bullish
TSE:BHC Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $15.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 5.3%
Last 30 Days ▼ 4.4%
Last 30 Days ▼ 4.4%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-18.19%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-0.59%
Trailing 12-Months
Company Description
Bausch Health Companies
Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on the vision care, surgical, and consumer, surgical, and ophthalmic pharmaceuticals products. The Salix segment provides gastroenterology products in the United States. The International Rx segment offers Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Ortho Dermatologics segment provides dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment offers pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
BHC Company Deck
BHC Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a generally positive operational and financial picture: strong revenue and EBITDA growth, robust cash generation (> $1 billion adjusted operating cash flow for 2025), meaningful debt and maturity profile improvements, targeted M&A to strengthen strategic footholds (notably in China), and advancement of a promising larsucosterol Phase III program. Key negatives include the RED-C Phase III failures, one-time Q4 impacts related to Solta China integration, margin pressure (adjusted gross margin down 80 bps), a Q4 timing-related reduction in adjusted operating cash flow for the Bausch Health segment, and medium-term risks to Xifaxan from Medicare rebate changes and generic/patent litigation uncertainty that imply a likely EBITDA step-down in 2027. Overall, the positives (consistent multi-quarter growth, strong cash flow, balance sheet repair, and targeted BD/portfolio investments) outweigh the setbacks, though the company flagged clear near- and medium-term headwinds that investors should monitor.View all TSE:BHC earnings summariesBHC Revenue Breakdown
47.34% Bausch + Lomb
25.69% Salix
12.23% International
10.77% Diversified Products
3.96% Solta Medical
BHC Stock 12 Month Forecast
Average Price Target
C$10.25
▲(22.44% Upside)
Technical Analysis
Knight Therapeutics
―
Cipher Pharmaceuticals
―
Cronos Group
―
HLS Therapeutics Inc
―
DRI Healthcare
―
Options Prices
Currently, No data available
---